ACE-031 is an experimental myostatin inhibitor. Here’s what the literature actually supports. Research and preclinical reference only.
The Short Answer
ACE-031 is a soluble activin receptor type IIB (ActRIIB) fusion protein designed to block myostatin and related ligands, and it’s studied for its effects on muscle growth in preclinical models. It’s a research compound with no approved therapeutic use.
Mechanism
ACE-031 works as a decoy receptor — it binds myostatin and other negative muscle regulators before they can activate the ActRIIB signaling pathway, removing the brake on muscle growth. That “decoy receptor” design is the core of how it functions.
- Class: soluble ActRIIB fusion protein
- Target: myostatin and related ligands
- Effect: reduces inhibitory signaling on muscle
Research Status
ACE-031 progressed into early human trials for muscular dystrophy but was discontinued over safety concerns, leaving it primarily a preclinical research tool today. Its history matters — it’s not a benign or well-characterized compound.
Sourcing and Purity
Research-grade ACE-031 should be ≥98% pure by HPLC with mass spectrometry confirmation and a batch-matched COA, and buyers should be especially cautious given its discontinued clinical status. This is not a peptide to source casually.
FAQ
Q: What is ACE-031 used for?
A: ACE-031 is a myostatin inhibitor studied in preclinical research for muscle-related conditions, but it was discontinued in human trials over safety concerns. It is research-use only.
Q: Is ACE-031 approved for human use?
A: No — ACE-031 was discontinued in clinical development and has no regulatory approval. It is sold strictly as a research compound.
Q: What purity should research-grade ACE-031 have?
A: Aim for ≥98% purity by HPLC with MS confirmation and a batch-matched COA from an independent lab. Given its status, verify the source carefully.